TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01581398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ypeginterferon alfa-2b
Description: sc, qw, 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: sc, qw, 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ypeginterferon alfa-2b
Description: sc, qw, 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegasys
Description: sc, qw, 48 weeks.
Study: NCT01939847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment suggestion
Description: Based on any actionable findings of the molecular profiling results, the investigators will come up with a suggestion for approved treatment or for clinical trial by referencing institutional clinical trials or potentially nationwide possibilities (www.clinicaltrials.gov).
Study: NCT03698825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEW-7197
Description: TEW-7197 50mg tablets + Paclitaxel 80 mg/m2 D1, 8, 15 q 4 weeks TEW-7197 dose will be determined through this dose escalation study
Study: NCT04737447

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole Body Vibration Training
Description: Galileo® Trainer is a vibration board. The movement alternating to different sides during walking correlates with the movement on the board due to variable amplitudes and frequencies. Movements of the vibration board are quickly changing and thus simulating the tilting movements of the pelvic during walking but with higher frequency. Muscles of legs and core are activated reflexively. In our study there are performed static practices and pelvic activating practices. Each physiotherapist is experienced in the technical and practical handling of the device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole Body Vibration Training
Description: Galileo® Trainer is a vibration board. The movement alternating to different sides during walking correlates with the movement on the board due to variable amplitudes and frequencies. Movements of the vibration board are quickly changing and thus simulating the tilting movements of the pelvic during walking but with higher frequency. Muscles of legs and core are activated reflexively. In our study there are performed static practices and pelvic activating practices. Each physiotherapist is experienced in the technical and practical handling of the device.
Study: NCT02329834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fursemide Injection Solution for subcutaneous administration (80 mg)
Description: Furosemide Injection Solution, 10mL of undiluted buffered furosemide solution (8mg/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fursemide Injection Solution for subcutaneous administration (80 mg)
Description: Furosemide Injection Solution, 10mL of undiluted buffered furosemide solution (8mg/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection, USP
Description: Furosemide Injection, USP (10mg/mL), 80 mg by intravenous administration.
Study: NCT01915030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein diet
Description: controlled feeding trail. Both arms are caloric restricted

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard protein diet
Study: NCT02826629

Intervention type: DEVICE
Group type: OTHER
Intervention: Manual dexterity
Description: Control of manual dexterity will be assessed by a force sensor (Power Grip Manipulandum, PGM)

Intervention type: DEVICE
Group type: OTHER
Intervention: Manual dexterity
Description: Control of manual dexterity will be assessed by a force sensor (Power Grip Manipulandum, PGM)

Intervention type: DEVICE
Group type: OTHER
Intervention: Manual dexterity
Description: Control of manual dexterity will be assessed by a force sensor (Power Grip Manipulandum, PGM)

Intervention type: DEVICE
Group type: OTHER
Intervention: Manual dexterity
Description: Control of manual dexterity will be assessed by a force sensor (Power Grip Manipulandum, PGM)

Intervention type: DEVICE
Group type: OTHER
Intervention: Oculomotor movements
Description: Oculomotor movements during behavioral task will be recorded using a video-oculography device

Intervention type: DEVICE
Group type: OTHER
Intervention: Oculomotor movements
Description: Oculomotor movements during behavioral task will be recorded using a video-oculography device

Intervention type: DEVICE
Group type: OTHER
Intervention: Oculomotor movements
Description: Oculomotor movements during behavioral task will be recorded using a video-oculography device

Intervention type: DEVICE
Group type: OTHER
Intervention: Oculomotor movements
Description: Oculomotor movements during behavioral task will be recorded using a video-oculography device
Study: NCT04462705

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual physiotherapeutic intervention and Abdominal Massage
Description: Abdominal massage is not widely applied amongst general surgery team and is not part of the recommendation. This technique refers to profound manœuvrers of visceras through abdominal palpation and breathing, and has been used as part of the local protocol of Grenoble Alps University Hospital for many years with satisfactory results. No complications have been reported.
Study: NCT02826629

Intervention type: DEVICE
Group type: OTHER
Intervention: TMS coupled to EMG recording
Description: The involvement of cortical inhibition in this volitional inhibition task will be studied by neuronavigation guided TMS coupled to EMG recording

Intervention type: DEVICE
Group type: OTHER
Intervention: TMS coupled to EMG recording
Description: The involvement of cortical inhibition in this volitional inhibition task will be studied by neuronavigation guided TMS coupled to EMG recording

Intervention type: DEVICE
Group type: OTHER
Intervention: TMS coupled to EMG recording
Description: The involvement of cortical inhibition in this volitional inhibition task will be studied by neuronavigation guided TMS coupled to EMG recording

Intervention type: DEVICE
Group type: OTHER
Intervention: TMS coupled to EMG recording
Description: The involvement of cortical inhibition in this volitional inhibition task will be studied by neuronavigation guided TMS coupled to EMG recording
Study: NCT01241032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: 200mg Single Oral Dose of

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Udenafil
Description: 200mg Single Oral Dose of
Study: NCT02826629

Intervention type: OTHER
Group type: OTHER
Intervention: Psychopathological evaluations

Intervention type: OTHER
Group type: OTHER
Intervention: Psychopathological evaluations
Study: NCT01241032

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Alcohol 39g / 240ml
Study: NCT02826629

Intervention type: OTHER
Group type: OTHER
Intervention: Psychopathological evaluations

Intervention type: OTHER
Group type: OTHER
Intervention: Psychopathological evaluations

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological evaluations

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological evaluations

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological evaluations

Intervention type: OTHER
Group type: OTHER
Intervention: Neuropsychological evaluations
Study: NCT03600389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Priorities Care
Study: NCT04810208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel in NanoZolid formulation, for intratumoural injection
Study: NCT03309761

Intervention type: OTHER
Intervention: Blood test
Description: 6ml blood sample taken
Study: NCT06352021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kaleidoscope
Description: The children in the kaleidoscope group were shown the kaleidoscope by the researcher five minutes before the blood sampling, and they were encouraged to look at the kaleidoscope during the procedure and describe the patterns they saw. All children in the Kaleidoscope group agreed to participate in the study. All children in the kaleidoscope group were asked to look at the kaleidoscope just before the tourniquet was placed on their arms before the blood sampling procedure and to describe the patterns, they saw in it by turning it slowly during the procedure.
Study: NCT01982682

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation (TBI)
Description: Undergo TBI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion (DLI)
Description: Undergo DLI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (HSCT)
Description: Undergo CD34+ selected allogeneic HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Given IV
Study: NCT01069965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGP-15 100 mg QD
Description: Two 50 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGP-15 100 mg BID
Description: One 100 mg BGP-15 capsule by mouth in the morning; and one 100 mg BGP-15 capsule by mouth in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo BID
Description: Two Placebo capsules by mouth in the morning; and two Placebo capsules by mouth in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGP-15 200 mg QD
Description: Two 100 mg BGP-15 capsule by mouth in the morning; and two Placebo capsule by mouth in the evening
Study: NCT02928289

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VISCO360 ab interno canaloplasty surgery
Description: 360 degrees of viscodilation of Schlemm's canal

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Laser Trabeculoplasty (SLT)
Description: 360 degrees of selective laser trabeculoplasty
Study: NCT00695344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Everolimus 2 times per day, v.o., 2 years treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azathioprine or mycophenolate mofetil
Description: 2 times per day during 2 years
Study: NCT04240392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC)
Description: The sites randomized to CC will have 4-6 on-site support visits at the outset of the study. These visits will occur during the first 3 months of the project. During these visits, study staff will again review buprenorphine induction procedures (heretofore referred to as initiation rather than induction) and dosing of buprenorphine as well as therapeutic behavioral treatments. The investigators will provide the center with forms and educational materials as well as an app that can be run to help dosing during initiation procedures. At the same time, the investigators will teach obstetricians, nurses and support staff the principles of motivational interviewing. The investigators will set up visits for the CM to meet with a recovery coach trainer provided by the investigators' community partner.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extension for Community Healthcare Outcomes (ECHO)
Description: The Weitzman Institute (WI), a community partner and provider for the ECHO condition, is a research and innovation center focused on improving care for medically underserved and special populations. Since 2013, CHCI/WI has provided education and technical assistance through an established video conference and online learning platforms to over 800 primary care providers and over 200 care team members who treat patients with chronic pain and opioid addiction. WI partners with national experts in pain care, substance abuse disorder, and MAT to create and deliver a robust training program for clinicians across the country through Project ECHO ®. The WI will work with the study team to develop and staff the sessions.
Study: NCT03469232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huanglian-Jiedu Decoction
Description: Huanglian-Jiedu Decoction includes 4 kinds of Chinese herbs as following: Huanglian (Rhizoma Coptidis), Huangbo (Cortex Phellodendri), Huangqin (Scutellaria baicalensis) and Zhizi (Scutellaria baicalensis). All of them were prepared as granule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huanglian-Jiedu Decoction
Description: Huanglian-Jiedu Decoction includes 4 kinds of Chinese herbs as following: Huanglian (Rhizoma Coptidis), Huangbo (Cortex Phellodendri), Huangqin (Scutellaria baicalensis) and Zhizi (Scutellaria baicalensis). All of them were prepared as granule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huanglian-Jiedu Decoction
Description: Huanglian-Jiedu Decoction includes 4 kinds of Chinese herbs as following: Huanglian (Rhizoma Coptidis), Huangbo (Cortex Phellodendri), Huangqin (Scutellaria baicalensis) and Zhizi (Scutellaria baicalensis). All of them were prepared as granule.
Study: NCT03207984

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Root coverage surgery
Description: Periodontal plastic surgery aiming the treatment of multiple gingival recessions in aesthetics areas with SCTG and CM

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root coverage surgery
Description: Periodontal plastic surgery aiming the treatment of multiple gingival recessions in aesthetics areas with SCTG and CM
Study: NCT00592306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thymoglobulin (intraoperative)
Description: All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.~Each arm will also receive a single placebo dose.~Arm I will receive thymoglobulin intraoperatively followed by a postoperative placebo dose and two subsequent thymoglobulin doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: thymoglobulin (postoperative)
Description: All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.~Each arm will also receive a single placebo dose.~Arm II will receive placebo intraoperatively followed by 3 postoperative doses of thymoglobulin.
Study: NCT00245518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflavone
Study: NCT01069965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGP-15 200 mg BID
Description: Two 100 mg BGP-15 capsules by mouth in the morning; and two 100 mg BGP-15 capsules by mouth in the evening

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGP-15 400 mg QD
Description: Two 200 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
Study: NCT05301010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faceptor
Description: NNG-TMAB (trastuzumab) 150 mg, 440 mg, lyophilized power for injection, manufacturered by Nanogen Pharmaceutical Biotechnology JSC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin
Description: Herceptin (trastuzumab) 150mg, 440mg, powder for concentrate for solution, manufactured by Roche.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: The drug Docetaxel in this study has the brand name Taxotere manufactured by Sanofi company.
Study: NCT01403493

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Study: NCT01340053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791
Description: Capsule, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791
Description: Capsule, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDX5791
Description: Capsule, QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RDX5791
Description: Capsule, QD
Study: NCT05028335

Intervention type: OTHER
Group type: OTHER
Intervention: Carbamide Peroxide (PC) 22%) + placebo gel
Description: Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them. The volunteers were instructed to apply a small amount of placebo gel, without active ingredient, with color, texture and odor similar to 1.5% oxalate gel (Painless, BM4, SC, Brazil) in the spaces related to the vestibular portions of the teeth trays, which were used for 10 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbamide Peroxide (PC) 22%) + Potassium Oxalate gel 1.5%
Description: Application of one drop of Polanight bleaching agent (SDI, SP, Brazil) on each corresponding tooth in a tray that was used for 45 minutes a day, for a period of twenty-one days. After the bleaching treatment, the participants were instructed to wash the trays under running water and dry them with absorbent paper. The volunteers applied a small amount of 1.5% potassium oxalate gel (Painless, BM4, SC, Brazil) in the spaces relative to the vestibular portions of the tray's teeth, which were used for 10 minutes.
Study: NCT00955539

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AV-optimization followed by AV- and VV-optimization
Description: Patients are AV-optimized the first 4 months,then AV- and VV-optimized the next 4 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AV- and VV-optimization followed by AV-optimization only.
Description: Patients are AV- and VV-optimized the first 4 months,then AV-optimized the next 4 months.
Study: NCT04264156

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lucinactant for Inhalation
Description: A drug-device combination product that delivers aerosolized SRT to preterm neonates with RDS who are being supported with nasal continuous positive airway pressure (nCPAP).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: nCPAP Only
Description: Nasal continuous positive airway pressure (nCPAP) alone
Study: NCT04706442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Parenting Application
Description: The Supportive Parenting Application is a theory-based perinatal educational intervention for couples administered through a mobile application. The mobile app consist of knowledge-based content, informational videos and audio, discussion forum, chat groups with peer volunteers, and an experts advice section
Study: NCT04394585

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smart phone app based human coaching program
Description: 1. experimental arm~   * 1:1 coaching using smart phone app~  * Patients are provided several articles about postoperative care (symptom management, diet, and exercise) in the app.~  * Patients are encouraged to report their diet diaries and exercise everyday by the coach.~  * Patients can ask to the coach using the app and the coach answer when they check them.~2. Comparator arm - Patient have consulting with clinical nutritionist at 1 month and 3 months postoperatively.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smart phone app based human coaching program
Description: 1. experimental arm~   * 1:1 coaching using smart phone app~  * Patients are provided several articles about postoperative care (symptom management, diet, and exercise) in the app.~  * Patients are encouraged to report their diet diaries and exercise everyday by the coach.~  * Patients can ask to the coach using the app and the coach answer when they check them.~2. Comparator arm - Patient have consulting with clinical nutritionist at 1 month and 3 months postoperatively.
Study: NCT02329834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection, USP
Description: Furosemide Injection, USP (10mg/mL), 80 mg by intravenous administration.
Study: NCT04234841

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Blood test

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Blood test
Study: NCT04447183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Thyroid Stimulating Hormone for Injection(rhTSH)
Description: rhTSH: 0.9 mg IM daily on two consecutive days;radioactive iodine: 30mCi±1.5mCi or 1.11GBq of 131I oral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: radioactive iodine
Description: radioactive iodine: 30mCi±1.5mCi or 1.11GBq of 131I oral

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: radioactive iodine
Description: radioactive iodine: 30mCi±1.5mCi or 1.11GBq of 131I oral
Study: NCT02700893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atropine+ propofol
Description: Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants \< 1000g - Renewable once 2.5 mg/kg for infants \> 1000G - Possible additional dose of 1 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atropine + atracurium + sufentanil
Description: Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants \< 1000g 0.2 µg/kg for infants \> 1000g
Study: NCT02415907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [ethyl-1-14C]-idalopirdine
Description: 120 mg/2.40 MBq Lu AF67708 (\[ethyl-1-14C\]-idalopirdine) in one capsule for oral administration, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [benzyl-7-14C]-idalopirdine
Description: 120 mg/2.40 MBq Lu AF67709 (\[benzyl-7-14C\]-idalopirdine) in one capsule for oral administration, single dose
Study: NCT03315780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC
Study: NCT04106674

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open reduction internal stabilisation (ORIF)
Description: Treatment allocated to surgical or non-surgical group. Implant choice pragmatic, surgeons choice.
Study: NCT04462705

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Usual physiotherapeutic intervention and Abdominal Massage
Description: Abdominal massage is not widely applied amongst general surgery team and is not part of the recommendation. This technique refers to profound manœuvrers of visceras through abdominal palpation and breathing, and has been used as part of the local protocol of Grenoble Alps University Hospital for many years with satisfactory results. No complications have been reported.
Study: NCT04036656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA136 0.5 mg
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHA136 1 mg
Description: oral tablet
Study: NCT01716546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib